Syst-Eur

Cardiology A trial designed to evaluate the effectiveness of isolated antihypertensive therapy in preventing cardiovascular complications in elderly Pts with isolated systolic HTN. See Antihypertensive, Calcium channel blockers, Hypertension.

Mentioned in ?

trial

References in periodicals archive ?

The calcium channel blocker nitrendipine was chosen as the comparator agent because of its success in the Syst-Eur study(2) where treatment reduced the risk of stroke by 42% in elderly patients with systolic hypertension.

TEVETEN (eprosartan) Reduces Future Risk in Hypertensive Stroke Patients

In a Syst-Eur substudy of 492 diabetic patients with isolated systolic hypertension, the dihydropyridine calcium channel blocker resulted in a 63% reduction in cardiac events, a 73% decrease in strokes, and a 76% drop in mortality due to cardiovascular disease.

[beta]-blockers not first line in systolic hypertension. (Cardiovascular Medicine: Select diuretics, calcium channel blockers)

SYST-EUR, a major clinical trial on the calcium channel blocker (CCB) nimodipine found that subjects receiving the drug experienced 42% fewer strokes and 31% fewer cardiac events.

ITALY - CALCIUM CHANNEL BLOCKERS REDUCE STROKES

The Syst-Eur trial (14) was one of the early trials intended to show the benefit of antihypertensive therapy in the prevention of stroke in patients with isolated systolic hypertension.

Treatment of chronic hypertension for the prevention of stroke. (Featured CME Topic: Stroke)

Weber commented further: "Two major international clinical trials that finished during the last couple of years, Syst-Eur and HOPE, dosed their principal cardiovascular drugs at night and reported significant survival benefits as well as reductions in serious events like strokes and heart attacks.

Biovail Reports Positive Cardizem XL Clinical Results

23 /PRNewswire/ -- The risk of dementia in elderly people with high blood pressure can be halved by treatment with the long-acting calcium channel blocker nitrendipine, according to the latest results from the Syst-Eur trial, published in the October 24 issue of The Lancet (Lancet 1998; Vol 352: 1347-1351).

Treatment of 1000 hypertensive patients for five years could prevent nineteen cases of dementia; the benefits could even be larger in higher-risk groups", reported Professor Forette, University of Paris V, Hopital Broca, the lead investigator of the Vascular Dementia Project in the Syst-Eur trial (1).

It is important to note that the beneficial effect regarding dementia occurred over and above the reductions in cardiovascular endpoints and strokes achieved by the drugs in the Syst-Eur trial (1).

Antihypertensive Treatment Prevents Dementia Breakthrough In a Clinical Trial Using a Long-Acting Calcium Channel Blocker

The rationale behind the Joint Committee's decision to include long-acting dihydropyridine calcium antagonists (eg, once-daily nifedipine) for the treatment of isolated systolic hypertension was due to compelling evidence demonstrated by the SYST-EUR (Systolic Hypertension in Europe) study, published in The Lancet in September 1997, which showed a major reduction in the incidence of cardiovascular events.

Nifedipine (Adalat(R)) Restores Endothelial Function, According to Bayer AG

Alberto Zanchetti, Syst-Eur investigator and Immediate Past President of the European Society of Hypertension said, "This is a landmark study, the results of which were expected with great interest by the medical community.

Safety of Calcium Channel Blockers in the Syst-Eur Trial

The Syst-Eur trial had a more rigorous design because it was prospective, double-blind and placebo controlled.

First Long-Term Study Demonstrates Reduction in Stroke, Heart Attack Death in Elderly Patients Taking Calcium Channel Blocker